AI Identifies Potential Prostate Cancer Treatment
The platform suggests combining berberine with enzalutamide to help overcome treatment resistance in laboratory models.
Updated on Oct. 26, 2026 in Cancer
Live Poll
Do you trust artificial intelligence to improve the discovery of effective new medical treatments?
UCLA researchers developed an AI platform named MAESTRO to identify effective cancer drug combinations, discovering that berberine shows potential synergy with enzalutamide. The findings, published in 2026, suggest a new computational method for overcoming drug resistance in prostate cancer.
Why it matters
Prostate cancer often becomes resistant to enzalutamide by activating alternative survival pathways, making combination therapies essential for effective long-term treatment. This AI approach helps identify synergistic candidates more efficiently than traditional screening.
In a 2026 preclinical study using AI-driven screening, researchers identified 23 natural products showing synergy with enzalutamide out of 3,592 candidates. The findings remain preliminary, as the efficacy of the berberine combination has only been confirmed in 3D prostate cancer cell models.
The players
UCLA
A public research university where the computational oncology team conducted this drug synergy study.
The details
The MAESTRO platform uses large language models to analyze biological pathway data and drug interactions, evaluating each candidate over 100 times to ensure consistency. By identifying berberine as a synergistic partner for enzalutamide, the system demonstrated an ability to increase AMPK activity while simultaneously suppressing mTORC1 signaling. This dual action is intended to block the alternative survival pathways that prostate cancer cells typically use to bypass enzalutamide treatment.
Timeline
The research was published in Advanced Science in 2026.
Health Landscape
This development represents a shift toward using artificial intelligence to navigate the complex biological pathways involved in treatment resistance. It builds on existing research into precision oncology by automating the discovery of synergistic drug combinations that were previously labor-intensive to identify.
These findings are currently limited to laboratory models and do not change existing prostate cancer treatment protocols. Patients should continue their current prescribed regimens and discuss any questions about new research or experimental combinations with their oncologist.
The takeaway
While AI-led drug discovery is accelerating the identification of potentially powerful combination therapies, these laboratory results represent early-stage research. Patients managing prostate cancer should focus on strictly adhering to current treatment plans and consulting with their care team regarding any new developments.
Further reading
Learn more about evolving research and treatment approaches in our Cancer section.
More information
View the complete scientific study in Advanced Science for detailed methodology and findings.
Source note: This article includes information reported by Technology Networks.
Live Poll
Do you trust artificial intelligence to improve the discovery of effective new medical treatments?
